AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
National Healthcare's 15min chart shows MACD Death Cross, bearish Marubozu pattern.
ByAinvest
Wednesday, Sep 24, 2025 11:42 am ET1min read
National Healthcare's 15-minute chart recently exhibited a MACD Death Cross, accompanied by a Bearish Marubozu candlestick pattern at 09:30 on September 24, 2025. This technical indicator suggests that the stock price may continue to decline, as sellers have taken control of the market and bearish momentum is likely to persist.
Viemed Healthcare Inc. (NASDAQ: VMD), a leading provider of home-based respiratory care solutions, has experienced notable financial growth and strategic acquisitions in recent quarters. The company reported strong Q2 2025 financial results, with record net revenues of $63.1 million, up 14.7% year-over-year. Net income reached $3.2 million ($0.08 per diluted share), a 115.1% increase from Q2 2024. The company's Adjusted EBITDA grew 11.5% to $14.3 million [1].Key highlights include significant patient growth, with ventilator patients up 11.4% to 12,152 and PAP therapy patients increasing 51.4% to 26,260. Additionally, Viemed completed a $26 million acquisition of Lehan's Medical Equipment on July 1, 2025, which generated $25.7 million in net revenues and $7.4 million in Adjusted EBITDA in 2024. The acquisition strengthens Viemed's presence in post-acute respiratory healthcare and expands its geographical footprint .
Technical indicators also provide insights into Viemed's stock performance. On September 24, 2025, the 15-minute chart of National Healthcare exhibited a MACD Death Cross, accompanied by a Bearish Marubozu candlestick pattern at 09:30. This suggests that the stock price may continue to decline, as sellers have taken control of the market and bearish momentum is likely to persist .
Despite the technical indicators, Viemed maintains a strong financial position with $20 million in cash and $55 million available in credit facilities. The company has raised its 2025 guidance, now expecting revenue between $271-277 million and Adjusted EBITDA of $59-62 million. CEO Casey Hoyt emphasized the company's confidence in its long-term outlook and commitment to shareholder value, supported by strong balance sheet and increasing free cash flow [1].
Viemed has also completed its share repurchase program, authorizing the buyback of up to 1,976,441 common shares (5% of outstanding shares) through June 2026. The program was executed at a weighted average price of $6.69 per share, totaling approximately $13.2 million .
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet